Featured content in this Issue:
- EQUULUS Therapeutics Emerges from Stealth with Non-Hallucinogenic Ibogaine Analog as Lead Candidate
- Responses to ICER’s Draft Evidence Report on MDMA-Assisted Psychotherapy for PTSD
- An Update on Health Canada’s Special Access Program
- Beckley Psytech Publishes Phase I Study of Intranasal 5-MeO-DMT (BPL-003)
- New NIH Funding Opportunity for Clinical Trials of Psychedelics for Chronic Pain in Older Adults
- Clairvoyant Therapeutics Targets Conditional Marketing Authorisation in Canada and EU
Companies, organisations and drug candidates mentioned in this Bulletin: EQUULUS Therapeutics; EQL-101; EQL-201; Gilgamesh Pharmaceuticals; DemeRx; atai Life Sciences; Delix Therapeutics; CaaMTech; Lykos Therapeutics; Beckley Psytech; BPL-003; Compass Pathways; Clairvoyant Therapeutics.
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
